Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.

Pedro López-RomeroInmaculada de la TorreEwa HaladyjDaniel Aletaha Josef S Smolen

Published in: Annals of the rheumatic diseases (2022)

Baricitinib reduces structural damage progression versus PBO with background MTX and/or MTX, even in patients with MDA/HDA, showing a disease-modifying effect across all disease activity states.

Keyphrases

disease activity
systemic lupus erythematosus
rheumatoid arthritis
rheumatoid arthritis patients
ankylosing spondylitis
juvenile idiopathic arthritis
oxidative stress
breast cancer cells
histone deacetylase
nitric oxide synthase
cell proliferation
cell cycle arrest